Related Experiment Videos
[The treatment of solid tumors with monoclonal antibodies]
W G Dippold1, K H Meyer zum Büschenfelde
1I. Medizinische Klinik und Poliklinik, Universität Mainz.
Immunitat Und Infektion
|February 1, 1989
Abstract:
Patients with B-cell lymphomas, gastrointestinal tumors and melanomas were treated in pilot and phase-I clinical studies with monoclonal antibodies directed to tumor-associated antigens in recent years. Side effects of this new treatment approach were minor. Tumor regressions were observed in all three groups of tumors.
Insights
Monoclonal antibodies targeting tumor antigens showed minor side effects and caused tumor regressions in patients with B-cell lymphomas, gastrointestinal tumors, and melanomas during early clinical trials.
Area of Science:
- Oncology
- Immunotherapy
- Clinical Research
Context:
- Recent pilot and phase-I clinical studies explored novel cancer treatments.
- Monoclonal antibodies targeting tumor-associated antigens represent a new therapeutic approach.
Purpose:
- To evaluate the safety and efficacy of monoclonal antibodies against tumor-associated antigens.
- To assess tumor response in patients with B-cell lymphomas, gastrointestinal tumors, and melanomas.
Summary:
- Patients with B-cell lymphomas, gastrointestinal tumors, and melanomas received treatment with monoclonal antibodies.
- The treatment approach demonstrated minor side effects.
- Tumor regressions were observed across all treated patient groups.
Impact:
- This early-phase research indicates the potential of monoclonal antibody therapy in diverse cancer types.
- The findings support further investigation into targeted antibody treatments for B-cell lymphomas, gastrointestinal tumors, and melanomas.